{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:15:04Z","timestamp":1792664104136,"version":"4.5.0"},"reference-count":244,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.expneurol.2013.01.024","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T21:16:48Z","timestamp":1359235008000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Modeling dyskinesia in animal models of Parkinson disease"],"prefix":"10.1016","volume":"256","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2013.01.024_bb0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0010","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0306-4522(93)90444-K","article-title":"Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates","volume":"55","author":"Albanese","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6","article-title":"Dorsal subthalamotomy for Parkinson's disease","volume":"16","author":"Alvarez","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0020","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/jnnp.2008.154948","article-title":"Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36months","volume":"80","author":"Alvarez","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1006\/nbdi.1999.0259","article-title":"Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease","volume":"6","author":"Andersson","year":"1999","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0030","doi-asserted-by":"crossref","first-page":"e42652","DOI":"10.1371\/journal.pone.0042652","article-title":"The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats","volume":"7","author":"Aristieta","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.20296","article-title":"Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia","volume":"57","author":"Aubert","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0040","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/WNL.35.7.949","article-title":"Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases","volume":"35","author":"Ballard","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0045","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/mds.20370","article-title":"Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease","volume":"20","author":"Bara-Jimenez","year":"2005","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0050","series-title":"Parkinson's Disease: Current Progress, Problems and Management","first-page":"229","article-title":"High level levodopa therapy in several akinetic parkinsonian patients: twelve years later","author":"Barbeau","year":"1980"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0055","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0060","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/mds.10551","article-title":"Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease","volume":"18","author":"Baron","year":"2003","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0014-4886(71)90127-0","article-title":"Production of involuntary movements by L-dopa in monkeys with tegmental lesions","volume":"33","author":"Battista","year":"1971","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cell.2005.05.012","article-title":"An Akt\/beta-arrestin 2\/PP2A signaling complex mediates dopaminergic neurotransmission and behavior","volume":"122","author":"Beaulieu","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0075","doi-asserted-by":"crossref","first-page":"32072","DOI":"10.1074\/jbc.M606062200","article-title":"Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice","volume":"281","author":"Beaulieu","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tips.2007.02.006","article-title":"The Akt-GSK-3 signaling cascade in the actions of dopamine","volume":"28","author":"Beaulieu","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0085","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0006-8993(86)90783-3","article-title":"Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding","volume":"379","author":"Bedard","year":"1986","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0090","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/jn.1994.72.2.507","article-title":"The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism","volume":"72","author":"Bergman","year":"1994","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0100","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1523\/JNEUROSCI.17-12-04752.1997","article-title":"Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum","volume":"17","author":"Berretta","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0110","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","article-title":"Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models","volume":"57","author":"Bibbiani","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0115","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1471-4159.2011.07376.x","article-title":"Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels","volume":"118","author":"Bido","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0120","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0125","first-page":"1034","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0130","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.parkreldis.2004.02.011","article-title":"Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms","volume":"10","author":"Blanchet","year":"2004","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0135","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0014-2999(84)90238-3","article-title":"[3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy","volume":"99","author":"Bokobza","year":"1984","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","article-title":"Buspirone in levodopa-induced dyskinesias","volume":"17","author":"Bonifati","year":"1994","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0145","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1124\/jpet.111.189100","article-title":"Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats","volume":"340","author":"Bordia","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mds.870050103","article-title":"Induction of chorea and dystonia in parkinsonian primates","volume":"5","author":"Boyce","year":"1990","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF02245739","article-title":"Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys","volume":"102","author":"Boyce","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0160","first-page":"413","article-title":"Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons","volume":"174","author":"Breese","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0165","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mds.870130603","article-title":"Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease","volume":"13","author":"Brotchie","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0170","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1471-4892(02)00011-5","article-title":"CB1 cannabinoid receptor signalling in Parkinson's disease","volume":"3","author":"Brotchie","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0175","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1073\/pnas.80.14.4546","article-title":"A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"80","author":"Burns","year":"1983","journal-title":"PNAS"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0180","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1353-8020(02)00029-9","article-title":"Levodopa response motor complications \u2014 GABA receptors and preproenkephalin expression in human brain","volume":"8","author":"Calon","year":"2002","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","article-title":"Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment","volume":"26","author":"Calon","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0190","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0195","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01244978","article-title":"Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways","volume":"94","author":"Carlsson","year":"1993","journal-title":"J. Neural. Transm. Gen. Sect."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0205","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/syn.20527","article-title":"Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat","volume":"62","author":"Carta","year":"2008","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0210","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0215","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2013.01.024_bb0220","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S1353-8020(09)70782-5","article-title":"Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia","volume":"15","author":"Cenci","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0225","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0230","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2982.2008.01226.x","article-title":"Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism","volume":"21","author":"Chaumette","year":"2009","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0235","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2007.08.006","article-title":"In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?","volume":"209","author":"Chesselet","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0240","first-page":"299","article-title":"Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury","volume":"20","author":"Chong","year":"2005","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0245","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0022-510X(87)90041-4","article-title":"Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"78","author":"Clarke","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0250","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002826-198403000-00005","article-title":"L-Dopa methyl ester\u2014a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease","volume":"7","author":"Cooper","year":"1984","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0255","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1017\/S0317167100037859","article-title":"MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms","volume":"14","author":"Crossman","year":"1987","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0260","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0165-1781(79)90006-4","article-title":"Chronic Parkinsonism secondary to intravenous injection of meperidine analogues","volume":"1","author":"Davis","year":"1979","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0265","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","article-title":"Genetic animal models of Parkinson's disease","volume":"66","author":"Dawson","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0270","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/mds.870020302","article-title":"Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease","volume":"2","author":"de Yebenes","year":"1987","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0275","first-page":"141","article-title":"Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease","volume":"27","author":"de Yebenes","year":"1988","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0280","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0285","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/exnr.2002.7891","article-title":"Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway","volume":"175","author":"Deumens","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0290","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa060281","article-title":"A randomized trial of deep-brain stimulation for Parkinson's disease","volume":"355","author":"Deuschl","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0295","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000480624","article-title":"Priming as a model of behavioural sensitization","volume":"18","author":"Di Chiara","year":"1992","journal-title":"Dev. Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0300","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/1531-8257(200005)15:3<459::AID-MDS1006>3.0.CO;2-3","article-title":"Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model","volume":"15","author":"Di Monte","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2007.03.013","article-title":"Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease","volume":"27","author":"Ding","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0310","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1073\/pnas.1006511108","article-title":"Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice","volume":"108","author":"Ding","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0315","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.45.10.1855","article-title":"Levodopa-induced dyskinesias are improved by fluoxetine","volume":"45","author":"Durif","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0320","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0325","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0330","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0335","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.parkreldis.2012.01.020","article-title":"Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge","volume":"18","author":"Evans","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0340","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0014-2999(88)90750-9","article-title":"Behavioral and biochemical effect of chronic treatment with D-1 and\/or D-2 dopamine agonists in MPTP monkeys","volume":"150","author":"Falardeau","year":"1988","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0350","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1474-4422(12)70049-2","article-title":"Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation","volume":"11","author":"Fasano","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(96)00944-2","article-title":"Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats","volume":"321","author":"Fenu","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0360","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0","article-title":"Punding on L-dopa","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0365","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1056\/NEJMoa0907083","article-title":"Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease","volume":"362","author":"Follett","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0079-6123(10)84007-5","article-title":"The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future","volume":"184","author":"Fox","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2013.01.024_bb0375","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.23829","article-title":"The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease","volume":"26","author":"Fox","year":"2011","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0380","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.25133","article-title":"A critique of available scales and presentation of the non-human primate dyskinesia rating scale","volume":"27","author":"Fox","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0385","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2011.01.024","article-title":"Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease","volume":"42","author":"Francardo","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0390","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0014-2999(90)94802-5","article-title":"Effect of chronic treatment of MPTP monkeys with dopamine D-1 and\/or D- 2 receptor agonists","volume":"178","author":"Gagnon","year":"1990","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0395","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/cercor\/bhp317","article-title":"Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss","volume":"20","author":"Garcia","year":"2010","journal-title":"Cereb. Cortex."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.expneurol.2010.12.001","article-title":"The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys","volume":"228","author":"Gilmour","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0405","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-7091-6842-4_7","article-title":"Mechanism of 6-hydroxydopamine neurotoxicity","volume":"50","author":"Glinka","year":"1997","journal-title":"J. Neural. Transm. Suppl."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0410","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00002826-198212000-00003","article-title":"Drug holiday in the management of Parkinson disease","volume":"5","author":"Goetz","year":"1982","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0415","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0420","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0425","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","article-title":"Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys","volume":"16","author":"Gomez-Mancilla","year":"1993","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0430","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0006-8993(93)90694-I","article-title":"Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism","volume":"602","author":"Graham","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0435","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1471-1931(00)00027-6","article-title":"Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis","volume":"23","author":"Graybiel","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0440","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.294.5544.1024","article-title":"The neurobiology of slow synaptic transmission","volume":"294","author":"Greengard","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0445","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","article-title":"Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys","volume":"186","author":"Gr\u00e9goire","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0450","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gr\u00e9goire","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0455","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.parkreldis.2011.01.008","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys","volume":"17","author":"Gr\u00e9goire","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0460","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","article-title":"Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys","volume":"52","author":"Grondin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0465","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1460-9568.2006.05047.x","article-title":"Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission","volume":"24","author":"Gubellini","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0470","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1460-9568.2005.04196.x","article-title":"Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning","volume":"22","author":"Guigoni","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0475","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/ana.410190510","article-title":"Dopamine D2 receptor density remains constant in treated Parkinson's disease","volume":"19","author":"Guttman","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0480","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00002826-200007000-00005","article-title":"Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys","volume":"23","author":"Hadj Tahar","year":"2000","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0485","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","article-title":"Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys","volume":"15","author":"Hadj Tahar","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0490","series-title":"Textbook of Stereotactic and Functional Neurosurgery","first-page":"1539","article-title":"Pallidotomy for Parkinson's disease","author":"Hariz","year":"2009"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0495","doi-asserted-by":"crossref","first-page":"7850","DOI":"10.1523\/JNEUROSCI.22-18-07850.2002","article-title":"Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism","volume":"22","author":"Heimer","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0500","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/exnr.1998.6819","article-title":"Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease","volume":"151","author":"Henry","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.2001.7727","article-title":"Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"171","author":"Henry","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0510","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000120426","article-title":"Clinical cases where lesion therapy was chosen over deep brain stimulation","volume":"86","author":"Hooper","year":"2008","journal-title":"Stereotact. Funct. Neurosurg."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0515","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0520","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0525","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0304-3940(96)12884-6","article-title":"D3 receptor expression within the basal ganglia is not affected by Parkinson's disease","volume":"214","author":"Hurley","year":"1996","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0530","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ana.410420513","article-title":"Effects of apomorphine on globus pallidus neurons in parkinsonian patients","volume":"42","author":"Hutchison","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0535","doi-asserted-by":"crossref","first-page":"9107","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003","article-title":"3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates","volume":"23","author":"Iravani","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0540","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/j.1460-9568.2005.04308.x","article-title":"Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia","volume":"22","author":"Iravani","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0545","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0014-2999(72)90036-2","article-title":"Effects of 6-hydroxydopamine on putative transmitter substances in the central nervous system","volume":"18","author":"Jacks","year":"1972","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0550","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1353-8020(02)00115-3","article-title":"The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease","volume":"9","author":"Jenner","year":"2003","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0555","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","article-title":"The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"issue":"Suppl. 4","key":"10.1016\/j.expneurol.2013.01.024_bb0560","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1353-8020(09)70829-6","article-title":"From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease","volume":"15","author":"Jenner","year":"2009","journal-title":"Parkinsonism Relat. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0565","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(84)90467-1","article-title":"1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset","volume":"50","author":"Jenner","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0570","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/jpet.110.166629","article-title":"Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"333","author":"Johnston","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3171\/2012.9.JNS12295","article-title":"Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy","volume":"118","author":"Jourdain","year":"2013","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0580","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1046\/j.1471-4159.2001.00184.x","article-title":"Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation","volume":"76","author":"Kannari","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0585","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/01.wnl.0000310812.43352.66","article-title":"Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD","volume":"71","author":"Katzenschlager","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0590","first-page":"80","article-title":"Levodopa-induced dopamine receptor hypersensitivity","volume":"102","author":"Klawans","year":"1977","journal-title":"Trans. Am. Neurol. Assoc."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0595","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/jnnp.54.4.376-a","article-title":"Buspirone in the treatment of levodopa induced dyskinesias","volume":"54","author":"Kleedorfer","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0600","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","article-title":"Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia","volume":"34","author":"Klockgether","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0605","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1471-4159.2010.06776.x","article-title":"Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease","volume":"114","author":"Kobylecki","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0610","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1002\/mds.23867","article-title":"Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease","volume":"26","author":"Kobylecki","year":"2011","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0615","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.bbr.2006.02.030","article-title":"Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?","volume":"170","author":"Konitsiotis","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0620","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(01)03149-3","article-title":"6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase","volume":"922","author":"Kunikowska","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0625","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/mds.10263","article-title":"Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa","volume":"17","author":"Kuoppam\u00e4ki","year":"2002","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0630","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00702-007-0727-3","article-title":"L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates","volume":"114","author":"Kuoppam\u00e4ki","year":"2007","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0635","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/j.1460-9568.2007.05747.x","article-title":"High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats","volume":"26","author":"Lacombe","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0640","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","article-title":"Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis","volume":"219","author":"Langston","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0645","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0006-8993(84)90777-7","article-title":"Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey","volume":"292","author":"Langston","year":"1984","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0650","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/273059a0","article-title":"Receptor basis for dopaminergic supersensitivity in Parkinson's disease","volume":"273","author":"Lee","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0655","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1152\/jn.00443.2006","article-title":"Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns","volume":"97","author":"Lee","year":"2007","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0660","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0665","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1152\/jn.2001.86.1.249","article-title":"Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease","volume":"86","author":"Levy","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0670","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1523\/JNEUROSCI.5604-09.2010","article-title":"Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S","volume":"30","author":"Li","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0675","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2010.10.010","article-title":"Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys","volume":"17","author":"Lieu","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0680","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/WNF.0b013e3181b52792","article-title":"Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study","volume":"32","author":"Linazasoro","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0685","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bbr.2006.09.019","article-title":"The \u201cmotor complication syndrome\u201d in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration","volume":"177","author":"Lindgren","year":"2007","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0690","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/npp.2009.74","article-title":"Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease","volume":"34","author":"Lindgren","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0695","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0700","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.nbd.2004.01.007","article-title":"A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function","volume":"16","author":"Lundblad","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0705","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2005.02.002","article-title":"Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia","volume":"194","author":"Lundblad","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0710","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/mds.870070204","article-title":"Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification","volume":"7","author":"Luquin","year":"1992","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0715","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/BF00589907","article-title":"Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment","volume":"99","author":"Luthman","year":"1989","journal-title":"Psychopharmacology (Berl)"},{"issue":"Suppl. 12","key":"10.1016\/j.expneurol.2013.01.024_bb0720","first-page":"S308","article-title":"The impact and management of nonmotor symptoms of Parkinson's disease","volume":"17","author":"Lyons","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0725","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/syn.10291","article-title":"Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats","volume":"51","author":"Marin","year":"2004","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0730","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/syn.20941","article-title":"The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias","volume":"65","author":"Marin","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0735","series-title":"Movement Disorders","first-page":"96","article-title":"Nm Fluctuations of disability in Parkinson's disease - clinical aspects","author":"Marsden","year":"1982"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0740","series-title":"Primate Brain Maps: Structure of the Macaque Brain","author":"Martin","year":"2000"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0745","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJM198509193131204","article-title":"Reappraisal of temporary levodopa withdrawal (&quot;drug holiday&quot;) in Parkinson's disease","volume":"313","author":"Mayeux","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0750","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2003.12.034","article-title":"The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro","volume":"1004","author":"Mazzio","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0755","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3389\/fnint.2011.00019","article-title":"Perspective on the economic evaluation of deep brain stimulation","volume":"5","author":"McIntosh","year":"2011","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0760","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0765","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0770","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/02688690801971667","article-title":"Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study","volume":"22","author":"Merello","year":"2008","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0775","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1152\/physrev.1998.78.1.189","article-title":"Dopamine receptors: from structure to function","volume":"78","author":"Missale","year":"1998","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0780","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0149-7634(96)00036-X","article-title":"Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action","volume":"21","author":"Mitchell","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0785","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00008877-199508000-00010","article-title":"Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset","volume":"6","author":"Mitchell","year":"1995","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0790","series-title":"Adv Neurol","first-page":"665","article-title":"Experimental Dyskinesias in Normal Rhesus Monkeys","author":"Mones","year":"1973"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0795","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp.34.6.668","article-title":"Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism","volume":"34","author":"Mones","year":"1971","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0800","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0805","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.neuropharm.2012.07.036","article-title":"MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates","volume":"66","author":"Morin","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0810","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1046\/j.1460-9568.1998.00264.x","article-title":"Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies","volume":"10","author":"Morissette","year":"1998","journal-title":"Suppl. Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0815","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.pnpbp.2009.12.011","article-title":"Striatal Akt\/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys","volume":"34","author":"Morissette","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0820","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","article-title":"Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?","volume":"87","author":"Nadjar","year":"2009","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0830","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0079-6123(08)64236-3","article-title":"Reconsideration of ventrolateral thalamotomy for hyperkinesis","volume":"21","author":"Narabayashi","year":"1966","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0835","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1523\/JNEUROSCI.5031-09.2010","article-title":"High-Frequency Stimulation of the Subthalamic Nucleus and L-3,4-Dihydroxyphenylalanine Inhibit In Vivo Serotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease","volume":"30","author":"Navailles","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0840","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/mds.21235","article-title":"Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"22","author":"Nicholas","year":"2007","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0845","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.40.2.340","article-title":"Levodopa-induced dyskinesia: review, observations, and speculations","volume":"40","author":"Nutt","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0850","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1006\/exnr.2002.8009","article-title":"Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models","volume":"177","author":"Oh","year":"2002","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0855","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev.med.55.091902.104422","article-title":"The scientific basis for the current treatment of Parkinson's disease","volume":"55","author":"Olanow","year":"2004","journal-title":"Ann. Rev. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0860","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.50.3_Suppl_3.S1","article-title":"An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology","volume":"50","author":"Olanow","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0865","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","article-title":"Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)","volume":"27","author":"Olanow","year":"2004","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0870","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1212\/WNL.0b013e3181a1d44c","article-title":"The scientific and clinical basis for the treatment of Parkinson disease (2009)","volume":"72","author":"Olanow","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0875","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s12031-008-9137-8","article-title":"Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61\u20138048 in MPTP Monkeys with Levodopa-induced Dyskinesias","volume":"38","author":"Ouattara","year":"2009","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0880","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-4159.2010.06635.x","article-title":"Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys","volume":"113","author":"Ouattara","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0885","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.neuroscience.2010.03.022","article-title":"Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias","volume":"167","author":"Ouattara","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0890","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.neurobiolaging.2009.07.014","article-title":"Metabotropic glutamate receptor type 5 in levodopa-induced motor complications","volume":"32","author":"Ouattara","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0895","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1523\/JNEUROSCI.2949-06.2007","article-title":"High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease","volume":"27","author":"Oueslati","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0900","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0306-4522(93)90462-O","article-title":"Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey","volume":"55","author":"Page","year":"1993","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0905","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1185\/03007990902779319","article-title":"Levodopa-related wearing-off in Parkinson's disease: identification and management","volume":"25","author":"Pahwa","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0910","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/mds.21308","article-title":"Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias","volume":"22","author":"Paille","year":"2007","journal-title":"Mov. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(94)90796-X","article-title":"Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration","volume":"662","author":"Papa","year":"1994","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0920","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0165-0173(94)00008-D","article-title":"Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry","volume":"20","author":"Parent","year":"1995","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0925","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1353-8020(00)00058-4","article-title":"A re-evaluation of the current model of the basal ganglia","volume":"7","author":"Parent","year":"2001","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0930","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Parkinson Study Group","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0935","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0940","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/mds.870100606","article-title":"Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)","volume":"10","author":"Pearce","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0945","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s002130100733","article-title":"L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations","volume":"156","author":"Pearce","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0950","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-4615-1809-9_4","article-title":"MAP kinase-dependent pathways in cell cycle control","volume":"1","author":"Pelech","year":"1995","journal-title":"Prog. Cell Cycle Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0955","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1046\/j.1471-4159.2003.01960.x","article-title":"Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats","volume":"86","author":"P\u00e9rier","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0960","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/exnr.2001.7647","article-title":"Coadministration of (\u2212)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions","volume":"169","author":"Pirker","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0965","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1152\/jn.1960.23.5.534","article-title":"Experimental and histological study of midbrain dyskinesias","volume":"23","author":"Poirier","year":"1960","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0970","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0306-4522(00)00130-5","article-title":"Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment","volume":"98","author":"Quik","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0975","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0306-4522(02)00167-7","article-title":"Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey","volume":"113","author":"Quik","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb0980","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0985","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nbd.2012.06.009","article-title":"Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson&apos;s disease","volume":"48","author":"Quintana","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0990","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.870120503","article-title":"Is levodopa toxic to human substantia nigra?","volume":"12","author":"Rajput","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb0995","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1212\/WNL.0b013e3181ae7af1","article-title":"Course in Parkinson disease subtypes: A 39-year clinicopathologic study","volume":"73","author":"Rajput","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1001","series-title":"Animal Models of Movement Disorders","first-page":"401","article-title":"Behavioral Assessment in the African Green Monkey after MPTP Administration","author":"Redmond","year":"2012"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1005","first-page":"261","article-title":"Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration","volume":"1","author":"Richard","year":"2005","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1000","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb2000","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.870130506","article-title":"Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease","volume":"13","author":"Ryoo","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(75)90304-4","article-title":"Mechanisms of action of 6-hydroxydopamine","volume":"24","author":"Sachs","year":"1975","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1030","first-page":"101","article-title":"Wnt factors in axonal remodelling and synaptogenesis","volume":"65","author":"Salinas","year":"1999","journal-title":"Biochem. Soc. Symp."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1035","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ana.20738","article-title":"Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys","volume":"59","author":"Samadi","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1040","first-page":"19","article-title":"Functional neurochemistry of the basal ganglia","volume":"83","author":"Samadi","year":"2007"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1050","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1523\/JNEUROSCI.0852-07.2007","article-title":"Critical involvement of cAMP\/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia","volume":"27","author":"Santini","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1055","doi-asserted-by":"crossref","first-page":"e12322","DOI":"10.1371\/journal.pone.0012322","article-title":"Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia","volume":"5","author":"Santini","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1060","series-title":"Adv Neurol","first-page":"47","article-title":"Drug-induced Dyskinesia in Monkeys","author":"Sassin","year":"1975"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0091-3057(89)90372-9","article-title":"Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage","volume":"34","author":"Schneider","year":"1989","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0006-8993(90)90108-N","article-title":"Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys","volume":"534","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1075","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/mds.870130605","article-title":"Young-onset Parkinson's disease revisited\u2013clinical features, natural history, and mortality","volume":"13","author":"Schrag","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0301-0082(96)00015-9","article-title":"Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae","volume":"49","author":"Schwarting","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1085","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1001958023096","article-title":"MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences","volume":"30","author":"Sedelis","year":"2000","journal-title":"Behav. Genet."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1090","first-page":"720","article-title":"Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and \u22123 beta encoding genes","volume":"41","author":"Shaw","year":"1998","journal-title":"Genome"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1095","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7326\/0003-4819-138-8-200304150-00013","article-title":"Update on Parkinson disease","volume":"138","author":"Siderowf","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1100","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molbrainres.2004.09.017","article-title":"The MPTP model of Parkinson's disease","volume":"134","author":"Smeyne","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbr.2011.09.025","article-title":"Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia","volume":"226","author":"Smith","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1110","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/mds.870070311","article-title":"Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease","volume":"7","author":"Stocchi","year":"1992","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1115","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3171\/jns.2002.97.3.0598","article-title":"Subthalamotomy for advanced Parkinson disease","volume":"97","author":"Su","year":"2002","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/ana.410420519","article-title":"Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity","volume":"42","author":"Suarez","year":"1997","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1125","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0306-4522(00)00213-X","article-title":"L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset","volume":"99","author":"Svenningsson","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1130","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1073\/pnas.052712699","article-title":"DARPP-32 mediates serotonergic neurotransmission in the forebrain","volume":"99","author":"Svenningsson","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1135","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1460-9568.2011.07865.x","article-title":"Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia","volume":"34","author":"Tachibana","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1140","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2009.06.030","article-title":"Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides","volume":"58","author":"Tamim","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1145","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2013.01.024_bb1150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ana.1099","article-title":"Levodopa induces dyskinesias in normal squirrel monkeys","volume":"50","author":"Togasaki","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0014-2999(68)90164-7","article-title":"6-Hydroxy-dopamine induced degeneration of central monoamine neurons","volume":"5","author":"Ungerstedt","year":"1968","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"Ungerstedt","year":"1971","journal-title":"Acta Physiol. Scand. Suppl."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1165","first-page":"37","article-title":"6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome","volume":"2","author":"Ungerstedt","year":"1976","journal-title":"Pharmacol. Ther. B."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1073\/pnas.0408305102","article-title":"Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum","volume":"102","author":"Valjent","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1175","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2202-7-20","article-title":"Role of the ERK pathway in psychostimulant-induced locomotor sensitization","volume":"7","author":"Valjent","year":"2006","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1180","first-page":"480260","article-title":"Treatment of advanced Parkinson's disease","volume":"2010","author":"Varanese","year":"2011","journal-title":"Park. Dis."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000103410","article-title":"Stereotaxic intracerebral instillation of dopa","volume":"32","author":"Velasco Su\u00e1rez","year":"1970","journal-title":"Confin. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2013.01.024_bb1190","first-page":"13","article-title":"The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease","volume":"14","author":"Vidailhet","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1195","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1474-4422(04)00934-2","article-title":"Surgical treatment for Parkinson's disease","volume":"3","author":"Walter","year":"2004","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1200","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1152\/jn.00697.2006","article-title":"Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease","volume":"96","author":"Weinberger","year":"2006","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1205","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s002210050696","article-title":"Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates","volume":"125","author":"Wichmann","year":"1999","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.expneurol.2013.01.024_bb1210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2013.01.024_bb1215","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1016\/S1353-8020(11)70058-X","article-title":"Mouse models for LRRK2 Parkinson's disease","volume":"18","author":"Xu","year":"2012","journal-title":"Parkinsonism Relat. Disord."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861300037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861300037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:02:58Z","timestamp":1562612578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448861300037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":244,"alternative-id":["S001448861300037X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.01.024","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling dyskinesia in animal models of Parkinson disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2013.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}